Novo Nordisk A/S (NVO) FY2025Q2 Earning Prediction

08/06 04:00:00

Pre-Market

Novo Nordisk A/S (NVO) is set to release its FY2025Q2 earnings performance on 08/06 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 77.11B and an earnings per share (EPS) of 0.93 for the FY2025Q2. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueMISS

77.11B

76.86B

-0.33%

EPSBEAT

0.93

0.97

+4.30%

AI Summary

Attend Webcast

AI Earnings Prediction

Prediction for FY2025Q2

Earnings Date: Aug 6, 2025

The prediction suggests a 'Miss' for Novo Nordisk based on anticipated underperformance in U.S. sales, gross margin pressures, and limited international growth offset.

Miss

Last 0 quarters:

2 beats3 misses

Scenario Analysis

The AI analyzes the probability of each scenario occurring and identifies the triggering conditions.

Scenario

Prob.

Stock Reaction

Trigger Condition

Strong Beat

+5%

Accelerated Wegovy demand + FDA crackdown on compounding boosts U.S. sales.

Beat

15%

+2%

Better-than-expected international Wegovy uptake offsets U.S. softness.

Neutral

20%

Flat

Results align precisely with reduced guidance; no new negatives.

Miss

45%

-7%

U.S. obesity sales disappoint, gross margin deteriorates further.

Strong Miss

15%

-12%

Ozempic diabetes sales falter + Lilly’s Zepbound gains accelerate.

Unlock Free Scenario Probability

Key Indicators Forecast

The AI provides itemized forecasts for key indicators, potentially including revenue, EPS, gross margin, and free cash flow.

Revenue

EPS

Currency:

No data

Actual

Estimate

Metric

Prediction

Justification

Revenue

Miss

Wegovy/Ozempic U.S. growth likely below lowered guidance due to Lilly competition and compounding headwinds. International sales insufficient to offset.

EPS

Miss

Gross margin pressures (capacity expansion costs, pricing discounts) + elevated R&D spend (20% YoY increase) will weigh on profitability.

Unlock Free Key Indicators Forecast

Prediction Logic & Rational

Logic & Justification:
Novo Nordisk faces multiple headwinds from the Fact Data that strongly suggest underperformance against lowered expectations:

Market Share Erosion: HSBC and Barclays downgrades highlight persistent competition from illegal compounding and Eli Lilly’s Zepbound, which is gaining significant new patient starts. Novo’s termination of partnerships with Hims & Hers and pricing discounts (e.g., $299 Wegovy bundles) signal desperation to retain volume.
Guidance Cut Impact: The 13% stock drop on July 29 after slashing FY2025 sales and operating profit growth targets (to 8%-14% and 10%-16%, respectively) reflects structural challenges in U.S. obesity/diabetes markets and Wegovy’s lagging international penetration.
Regulatory/Pricing Pressures: Medicare/Medicaid coverage expansions (2026+) are too distant to offset near-term risks from Cigna’s $200/month Wegovy/Zepbound cap and California’s Medicaid cuts. Legal battles against knockoffs remain unresolved.
Pipeline Not Near-Term Catalysts: While Phase 3 trials for CagriSema and amycretin are promising, these will not materially impact Q2 results.

Prediction Logic & Rational

Tactical Strategy Recommendations

Bearish Options Plays:

Buy August $45 puts to hedge against downside from weak U.S. sales data.
Sell August $50 calls to capitalize on suppressed volatility post-earnings.

Pairs Trade: Short NVO vs. Long LLY, reflecting Lilly’s momentum in obesity market share.

Rationale: The stock’s -27% drop since last earnings already prices in some negativity, but Fact Data points to sustained execution risks. A Miss is the base case, with asymmetric downside risk if guidance is cut further.

Tactical Strategy Recommendations

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

NVO Transcript

Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript

Unknown11-5

The earnings call reveals several concerns: lowered sales and profit growth outlooks, market share loss in the GLP-1 market, and challenges in the U.S. obesity market. Despite some optimistic guidance and strategic initiatives, the lowered growth expectations and uncertainties in regulatory approvals and market dynamics create a negative sentiment, likely leading to a stock price decline of -2% to -8%.

Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript

Positive8-6

The earnings call reflects strong financial performance with an 18% sales growth and 20% operating profit increase. The company's strategic initiatives, such as partnerships and market expansions, are promising. While there are some uncertainties in litigation and pricing strategies, management's confidence in growth, particularly in China, and the launch of new products like oral Wegovy, supports a positive outlook. The guidance suggests continued strong performance, and there's optimism in overcoming challenges like LOE impacts. Overall, the sentiment is positive, with potential for stock price appreciation.

Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript

Unknown5-7

The earnings call presents a mixed outlook. Positive aspects include a 20% increase in operating profit, strong net profit growth, and a significant free cash flow increase. However, challenges are evident with a decreased gross margin, increased costs, and a significant net financial loss. The Q&A reveals uncertainties in market share dynamics and competitive pressures, with management providing vague responses. Despite positive shareholder returns, the lack of clear guidance and potential competitive risks balance the positives, leading to a neutral sentiment.

Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript

Positive11-6

The earnings call reveals strong sales and operating profit growth, a slight gross margin increase, and an optimistic sales growth outlook. However, concerns about regulatory risks, increased competition, and a significant impairment loss slightly temper the outlook. The Q&A section shows confidence in future growth, despite some uncertainties about product timelines. The share buyback program and raised guidance further support a positive sentiment. Overall, the positive financial performance and optimistic guidance outweigh the risks, suggesting a positive stock price movement in the near term.

NVO Report

Frequently Asked Questions

What is the Novo Nordisk A/S FY2025Q2 Earnings Release Date and Time?

Novo Nordisk A/S (NVO) is scheduled to release its FY2025Q2 earnings report onAug 6, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for Novo Nordisk A/S FY2025Q2 Revenue and EPS?

Analysts' consensus predicts 77.11B in revenue and an EPS of 0.93 for Novo Nordisk A/S's FY2025Q2.

What Does Intellectia's AI Predict for Novo Nordisk A/S FY2025Q2 Earnings?

Intellectia's exclusive AI algorithms forecast a Miss forNovo Nordisk A/S's FY2025Q2 earnings, with a prediction date of Aug 6, 2025. Novo Nordisk A/S The prediction suggests a 'Miss' for Novo Nordisk based on anticipated underperformance in U.S. sales, gross margin pressures, and limited international growth offset.

How Can I Use This Earnings Prediction to Trade NVO Stock?

Leverage Intellectia's AI forecast to position trades ahead of theAug 6, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like Novo Nordisk A/S FY2025Q2?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!